(Reuters) – FibroGen Inc said on Wednesday its drug to treat a type of neuromuscular disorder failed to meet the main goal in a late-stage study, sending the company’s shares down about 14% in premarket trading.
The treatment was generally safe and well tolerated for patients with Duchenne muscular dystrophy (DMD).
DMD is a progressive degenerative disorder that hampers muscle movement and affects one in 3,600 newborn boys, most of whom die by the age of 30.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar and Shounak Dasgupta)
